Stockreport

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments [Read more]